Trial Profile
Phase 1, Open-Label, Single-Arm, Clinical and Metabolomics Study of Dichloroacetate (DCA) in Adults With Recurrent Malignant Brain Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Sep 2015
Price :
$35
*
At a glance
- Drugs Sodium dichloroacetate (Primary)
- Indications Cancer metastases; Glioma
- Focus Adverse reactions
- 13 Aug 2013 Planned end date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 15 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.
- 15 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.